Bpifrance

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

Marion Aubry

Investment Director

Emmanuel Audouard

Director of Transverse Venture Capital Investments Division

Benoit Barteau Ph.D

Investment Director

Nicolas Berdou

Investment Director, Defense Expert

Clarisse Blandin

Investment Director

Elyssa Maufras du Châtellier

Investment Director

Edouard Combette

Investment Director

Charlotte Corbaz

Investment Drector - Large Venture

Sofia Dahoune

Associate

Nicolas Dardenne

Senior Investment Director, Normandy (Caen Rouen)

Arnaud Despoisse

Director of Occitanie Participations

Nicolas Dufourcq

CEO

Mailys Ferrere

Director of Large Venture Investments

Romain Fourcade

Investment Director

Paul-Francois Fournier

Executive Director, Innovation Department

Vanessa Giraud

Director of Environmental Impact Funds

Alessandro Gonella

Director

Gwenael Hamon

Investment Director

Laurent Higueret

Senior Investment Director, Healthcare and Life Sciences - Large Venture Fund

Veronique Jacq

Head of Digital Venture team

Louis Janneau

Investment Director and Fund Manager

Magali Joessel

Director of Funds

So-Yeon Koo

Senior Investment Manager

Jérôme Langlade

Investment Director Aquitaine / Limousin / Poitou-Charentes

Eric Lefebvre

Director

Stephane Lefevre-Sauli

Senior Investment Director

Arnaud Legardeur

Investment Director

Olivier Martinez

Investment Director

Serge Mesguich

Director of FIT

Louis Molis

Investment Director

Jean-Francois Morin

Investment Director

Sébastien Moynot

Director

Adrien Muller

Investment Director

Adrien Neel

Investment Director

Axel Piriou

Director of Investments

Olivier Rameil

Senior Investment Director / VC seed

Vincent Roque

Director

Thibaut Roulon Ph.D

Investment Director

Gilles Schang

Deputy Managing Director

Bruno Villeneuve

Associate

Jean-Marie Fougeray

Senior Investment Director, Brittany

Laure Michel

Investment Director

Past deals in Health Diagnostics

Poppins

Venture Round in 2025
Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

Vetbiolix

Venture Round in 2024
Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Vetbiolix

Seed Round in 2024
Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Enalees

Series A in 2024
Enalees develops molecular diagnostic tests for pets that can be used directly by veterinarians.

Archeon Medical

Venture Round in 2024
Archeon is fully dedicated to the development of innovative solutions for the monitoring, diagnosis and treatment of critically ill patients in prehospital care.

UroMems

Series C in 2024
UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Tribun Health

Grant in 2024
Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

Metyos

Pre Seed Round in 2024
Metyos is a Paris-based company specializing in wearable biosensor technology that monitors the effects of daily activities on nutrition and metabolism. By analyzing individual data, such as fat levels and energy metabolism dynamics, Metyos provides users with personalized fitness and nutrition plans. Their aim is to help individuals understand how their bodies respond to various actions, enabling them to make informed choices and effectively work towards their weight goals. Through this innovative approach, Metyos empowers users to regain control over their health and wellness.

Hawkcell

Series A in 2024
HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Bioptimus

Seed Round in 2024
Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Okomera

Grant in 2023
Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Steto

Seed Round in 2023
Steto Its mission is to create solutions for remote patient monitoring and digital diabetes therapies.

Poppins

Venture Round in 2023
Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

Tribun Health

Series B in 2023
Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

CorWave

Series C in 2023
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Moten Technologies

Seed Round in 2022
MOTEN Technologies specializes in muscle sensor technology and an analysis platform designed to prevent musculoskeletal disorders (MSDs) by measuring muscular effort. The company offers a range of services, including data processing, physical assistance, and analysis software. Their solutions enable decision-makers to optimize workstations and tasks for operators by monitoring body motion and associated muscular fatigue. By focusing on these areas, MOTEN Technologies aids companies in reducing the risks of MSDs, thereby promoting employee health and well-being.

DIVIE

Seed Round in 2022
Divie is a retail company that sells wellness products through its website. Their product categories such as drinks, oils, botanicals, herbal teas, isolates, plant oils, and infusions.

Valneva

Post in 2022
Valneva is a pharmaceutical company specializing in the development of prophylactic vaccines aimed at addressing infectious diseases with significant unmet medical needs. The company has successfully commercialized several vaccines, including IXIARO/JESPECT, DUKORAL, and IXCHIQ, primarily targeting travelers. In addition to its marketed products, Valneva is advancing a diverse pipeline of vaccine candidates, including those for Lyme disease, chikungunya, and COVID-19. The company is involved in the entire lifecycle of vaccine development, encompassing research, manufacturing, and distribution. Valneva also offers technologies and services aimed at enhancing vaccine commercialization, which further supports its mission to deliver life-saving immunizations globally.

Guerbet Group

Post in 2022
Guerbet is a human-scale company that aims to become a new global leader in medical imaging. Pioneer in contrast media with 90 years'​ experience, Guerbet is the only pharmaceutical group dedicated to medical imaging worldwide, with a presence in almost 80 countries via a network of subsidiaries and distributors. The company offers a comprehensive range of CT scan, Cath Lab, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostic (IRT) products, along with a range of injectors and related medical devices to improve patients'​ diagnosis, prognosis and quality of life.

BioMAdvanced Diagnostics

Venture Round in 2022
BioMAdvanced Diagnostics is a developer of molecular diagnostic and biomarker tests. These tests are intended to be integrated into conventional diagnostic and treatment protocols, to be simple to use for personnel caring for specific patients, and to be highly affordable. Its goal is to provide truly individualized care, which would dramatically enhance patient outcomes by giving physicians unparalleled tools.

Nurea

Seed Round in 2022
Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Sonio

Seed Round in 2022
Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Implicity

Series A in 2022
Implicity is a developer of a remote monitoring platform that specializes in the smart monitoring of patients with connected cardiac devices, such as pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on individual medical contexts. This capability allows cardiologists and healthcare professionals to automate the monitoring process, enabling them to effectively oversee patient health while consolidating information on a single platform. By streamlining remote monitoring, Implicity aims to enhance the quality of care provided to patients with cardiac implants.

Archeon Medical

Series A in 2022
Archeon is fully dedicated to the development of innovative solutions for the monitoring, diagnosis and treatment of critically ill patients in prehospital care.

NaoX Technologies

Venture Round in 2022
NaoX Technologies is focused on preventing neurological disorders through innovative connected solutions. The company has developed wireless headphones equipped with integrated sensors that passively monitor brain activity by detecting brain vibrations. These headphones record electroencephalogram data in real time and aggregate the information on a software dashboard for healthcare professionals. By providing this technology, NaoX Technologies aims to democratize access to neurological disorder prevention and support patients in their recovery from mental health issues.

Heroic sante

Seed Round in 2022
Heroic Sante is a virtual platform. They offer patients the chance to have their questions answered by qualified carers and learn from other patients. Their community works to create useful projects for patients and finances them thanks to statements on applications.

CORE for Tech

Venture Round in 2021
Core for Tech is a deep technology company focused on enhancing driver safety by measuring and predicting drowsiness while driving. Utilizing advanced technology that analyzes heart rate variability through native sensors or retrofit systems in vehicles, Core for Tech transforms this data into actionable insights about a driver's fatigue levels. By detecting drowsiness at an early stage, before it becomes visibly apparent, the company aims to provide timely information that enables drivers to make informed safety decisions. Through its innovative approach, Core for Tech seeks to contribute significantly to road safety and reduce the risks associated with driver fatigue.

Echoliv

Grant in 2021
Echoliv designs artificial intelligence solutions for abdominal ultrasound. They develop software to assist radiologists and hepatologists. The Ultraliv solution from Echoliv assists radiologists and hepatologists in early-stage ultrasound screening for the most common type of liver cancer, hepatocellular carcinoma (or HCC). The algorithm can detect nodules other than those identified by practitioners.

Provepharm life Solutions

Private Equity Round in 2021
Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

UroMems

Series B in 2021
UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Poppins

Seed Round in 2021
Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.

OncoDiag

Grant in 2021
OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urotest (CE-IVD) is a urine test for diagnosis and surveillance of bladder cancer. The company's pipeline also includes the Colodiag in development for early detection of colorectal cancer.

Omini

Seed Round in 2021
Omini is a French company, established in 2019 and based in Saint Mandé, that specializes in the development of portable and multipurpose bio-sensing devices for blood testing. The company’s biosensor platform allows for the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to tailor therapies and prevent acute crises in patients with chronic conditions. By employing advanced multiplex electrochemical biosensor technology, Omini's devices offer accurate and affordable solutions for identifying, analyzing, and monitoring various target biomarkers. This innovation supports decentralized testing and at-home monitoring, ultimately aiming to alleviate the burden on healthcare systems and improve patient outcomes. Omini primarily serves general practitioners, enhancing their ability to manage patient care effectively.

GRAPHEAL

Seed Round in 2021
Grapheal is a Medtech startup focused on developing embedded and wearable biosensors that leverage graphene transistors for enhanced functionality. Their devices are designed to be minimalistic and digital, enabling the dosing of biomarkers and detection of pathogens through a smartphone interface. By integrating advanced sensing nanomaterials with wireless connectivity and data analysis capabilities, Grapheal's biosensors facilitate field diagnostics and remote patient monitoring. This approach aims to make healthcare more accessible and accurate, allowing medical professionals to effectively monitor patient progress and healing.

Medaviz

Series A in 2020
Medaviz is an online platform founded in 2014 and headquartered in Paris, France, that facilitates immediate communication between patients and healthcare professionals. The service allows users to connect with various specialists, including general practitioners, pediatricians, gynecologists, and psychologists, at any time. By providing access to medical advice around the clock, Medaviz enables users to address their medical issues or emergencies efficiently, enhancing the convenience of healthcare access.

Withings

Series B in 2020
Withings is a developer of digital health and wellness smart devices. The company makes a range of products that empower people to make the right decisions for their health. Its digital health and wellness smart devices include a fitness watch that enables users to measure their heart rate.

UroMems

Series B in 2020
UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

UroMems

Debt Financing in 2020
UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Deinove

Post in 2020
Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Cardiologs

Series A in 2020
Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.

Deeplink Medical

Venture Round in 2019
Deeplink Medical develops a teleradiology platform aimed at enhancing telemedicine projects for healthcare professionals. Recognizing the limitations of existing telemedicine IT solutions, the company focuses on creating innovative tools that address real needs in the medical field. Their platform streamlines requests for imaging examinations, standardizes examination protocols, and ensures the secure transmission of essential data among healthcare providers. This approach allows users to operate independently in their teleradiology activities without reliance on a medical network. Additionally, Deeplink Medical emphasizes the importance of comprehensive support, training, and medical protocols to optimize patient management and ensure the success of telemedicine initiatives.

BioSerenity

Series B in 2019
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.

Neurallys

Seed Round in 2019
Neurallys is a Paris-based company specializing in the development and production of medical devices for neurology and neurosurgery. The company has created an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients with hydrocephalus. This innovative device aims to enhance patient comfort and provide neurosurgeons with a valuable tool for more effective management and follow-up of the condition, ultimately improving the quality of care for those affected by hydrocephalus.

Deinove

Post in 2019
Deinove SA is a biotechnology company based in Grabels, France, focused on discovering, developing, and producing microbial-derived compounds for the health, nutrition, and cosmetics sectors. The company is advancing its portfolio of antibiotic candidates, including DNV3837, which is currently undergoing Phase II clinical trials for treating Clostridioides difficile infections. In the cosmetics arena, Deinove offers various bioactive ingredients such as PHYT-N-Resist, Luminity, HEBELYS, and BIOME Oléoactif, which serve functions ranging from anti-aging to balancing skin microbiota. Additionally, Deinove is exploring processes for producing natural ingredients for animal feed. The company has established partnerships with several organizations, including bioMérieux and the Institut Pasteur, to enhance its research and development initiatives. Founded in 2006, Deinove is committed to leveraging its bacterial biodiversity to create sustainable solutions across multiple industries.

Happytal

Debt Financing in 2018
Happytal, founded in 2013 and based in Vanves, France, specializes in concierge services for hospitals. The company aims to enhance the patient experience by providing a range of services designed to promote comfort during hospital stays. These services include personal care options such as hairdressing and beautician services, as well as practical amenities like newspaper delivery and meal baskets. Happytal focuses on integrating local products and services, allowing patients to maintain their daily habits while receiving care. By offering these conveniences, Happytal seeks to improve the overall atmosphere for patients and their families within healthcare facilities.

C4Diagnostics

Seed Round in 2018
C4Diagnostics specializes in the development and commercialization of in vitro diagnostic (IVD) kits utilizing its proprietary technology. The company focuses on creating medical devices and equipment that enhance the speed and sensitivity of diagnostic tests. One of its primary offerings includes solutions for urinary tract infection screening, which reliably detects, counts, and concentrates culturable microorganisms relevant to clinical microbiology. This capability allows hospitals and laboratories to conduct culture-based IVD tests with improved accuracy and efficiency, contributing to better patient outcomes in diagnostic processes.

CORE for Tech

Venture Round in 2018
Core for Tech is a deep technology company focused on enhancing driver safety by measuring and predicting drowsiness while driving. Utilizing advanced technology that analyzes heart rate variability through native sensors or retrofit systems in vehicles, Core for Tech transforms this data into actionable insights about a driver's fatigue levels. By detecting drowsiness at an early stage, before it becomes visibly apparent, the company aims to provide timely information that enables drivers to make informed safety decisions. Through its innovative approach, Core for Tech seeks to contribute significantly to road safety and reduce the risks associated with driver fatigue.

CORE for Tech

Seed Round in 2018
Core for Tech is a deep technology company focused on enhancing driver safety by measuring and predicting drowsiness while driving. Utilizing advanced technology that analyzes heart rate variability through native sensors or retrofit systems in vehicles, Core for Tech transforms this data into actionable insights about a driver's fatigue levels. By detecting drowsiness at an early stage, before it becomes visibly apparent, the company aims to provide timely information that enables drivers to make informed safety decisions. Through its innovative approach, Core for Tech seeks to contribute significantly to road safety and reduce the risks associated with driver fatigue.

Cardiologs

Series A in 2017
Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.

BioSerenity

Series A in 2017
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.

Wynd

Series B in 2016
Wynd Technologies, Inc. is a manufacturer of air purifiers and a provider of environmental monitoring solutions aimed at enhancing indoor air quality. The company offers a range of products, including the portable Wynd air purifier, which features a removable sensor to monitor air quality and initiate purification. Wynd also provides advanced real-time air quality measurement and monitoring systems, with applications in both commercial and residential settings. Their solutions, such as Wynd Sentry and Wynd Nova, focus on detecting environmental disturbances and optimizing air quality, respectively, thereby improving health and safety in various environments, including hospitality and educational institutions. With a commitment to cloud-based technology, Wynd aims to integrate its air quality management systems into everyday appliances and HVAC systems, ensuring healthier spaces for users. Founded in 2014 and based in San Jose, California, Wynd Technologies was previously known as Claireau, Inc. before rebranding in 2015.

UroMems

Series A in 2016
UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

CorWave

Series B in 2016
CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Omind Neurotechnologies

Grant in 2016
Omind Neurotechnologies specializes in neurotraining services and content, harnessing applied neuroscience and neurotechnology to enhance individual and team performance. The company offers a comprehensive platform that includes a normative multimodal database, virtual reality stimuli, and real-time multimodal signal processing through its TimeFlux technology. Additionally, Omind maintains an anonymized repository known as Quetzal for research and development purposes. With a team of experts, including nine Ph.D. holders, the organization focuses on creating effective training strategies that promote emotional management, decision-making, and overall efficiency in everyday life for its clients. Through its emphasis on collective intelligence and group resilience, Omind aims to improve team dynamics and personal development.

Cardiologs

Seed Round in 2015
Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.

Magnisense

Grant in 2015
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires

Theravectys

Grant in 2015
Theravectys is a biotechnology company focused on developing a novel vaccine platform aimed at treating and preventing a wide array of infectious diseases, cancers, and other medical conditions. The company’s innovative vaccination technology utilizes gene transfer into dendritic cells to modulate the immune response, enhancing the effectiveness of both prophylactic and therapeutic immunotherapies. Their lead product, a therapeutic vaccine targeting HIV/AIDS, has demonstrated promising efficacy and safety in non-human primate studies and is set to enter clinical trials. Through its diverse pipeline, Theravectys aims to provide healthcare providers with advanced treatment options that elicit a potent and targeted immune response in patients.

Voluntis

Series D in 2014
Voluntis, Inc. is a healthcare software company headquartered in Cambridge, Massachusetts, that specializes in developing digital therapeutic solutions for various medical conditions, including diabetes and oncology. Founded in 2001, Voluntis provides innovative tools such as Insulia, which offers personalized insulin dose recommendations for type 2 diabetes patients, and Diabeo, designed for type 1 and type 2 patients on basal-bolus insulin regimens. These solutions utilize algorithmic calculations tailored to individual patient needs, incorporating real-time data like blood glucose levels. The company aims to enhance patient monitoring and support by leveraging advanced information and communication technologies. With over 600,000 patients managed and more than 50 programs deployed, Voluntis emphasizes a patient-centric approach to healthcare, striving to improve medical outcomes and healthcare system efficiency through its digital health solutions.

Skuldtech

Seed Round in 2013
Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.

Withings

Series B in 2013
Withings is a developer of digital health and wellness smart devices. The company makes a range of products that empower people to make the right decisions for their health. Its digital health and wellness smart devices include a fitness watch that enables users to measure their heart rate.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.